MetaCap

Replimune Group Inc. (REPL)

NASDAQ: REPLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

19.07-0.16 (-0.83%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

REPL stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.79
52-week range
1.50 – 23.54
Day range
18.70 – 19.50
Volume / Avg
1.96M / 2.48M
Beta
—

52-week range

$1.50$23.54

REPL stock today

Shares of Replimune Group (REPL) finished lower on Nov 20 at $19.07, a drop of 0.83% or $0.16 per share, versus the S&P 500's 3.70% decline. Shares are 19.0% below their 52-week high of $23.54, set on Nov 10, 2026 and 1171.3% above the 52-week low of $1.50, in the middle of the past year's range. REPL is up 96.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 107.3%.

Replimune Group has posted a net loss over the last twelve months (EPS of -$2.79), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Replimune Group

Company profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Sushil Patel Ph.D.
Headquarters
Woburn, MA
Employees
465
IPO year
2018

Financial highlights

Full financials

Replimune Group reported a net loss of $313.9 million, compared with a loss of $247.3 million a year earlier. Diluted earnings per share came in at -$3.38.

Replimune Group annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue—————
Growth—————
Net income$-313.94M$-247.30M$-215.79M$-174.28M$-118.04M
EPS (diluted)$-3.38$-3.07$-3.24$-2.99$-2.26

Analyst forecast

Forecast

Consensus (8 analysts)

buy

Avg. price target

$25.50+33.72%

  • Strong buy 2
  • Buy 5
  • Hold 0
  • Sell 1
  • Strong sell 0

Target range

Low $19.00High $31.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 28, 2026
EPS actual vs est.
$-0.54 vs $-0.70
Surprise
+22.86%

REPL news

All REPL news

Replimune Group peers

Health Care sector
REPL peer companies
CompanyPrice% ChgMarket capCompare
COAGHemab Therapeutics Holdings Inc.39.29-1.43%$1.84Bvs REPL
BCRXBioCryst Pharmaceuticals Inc.7.22-1.37%$1.86Bvs REPL
LYCALycia Therapeutics Inc.33.07+4.09%$1.72Bvs REPL
MAZEMaze Therapeutics Inc.31.37-3.27%$1.72Bvs REPL
VIRVir Biotechnology Inc.8.39-5.41%$1.56Bvs REPL
RXRXRecursion Pharmaceuticals Inc. Class A2.45-9.93%$1.53Bvs REPL
BEAMBeam Therapeutics Inc.20.90-0.19%$2.16Bvs REPL
ALVOAlvotech4.12-3.96%$1.47Bvs REPL

Indexes, lists and sector

Replimune Group stock FAQ

What is Replimune Group's stock price today?

REPL last traded at $19.07 as of Nov 20, 4:00 PM EST, down 0.83% on the day. Prices are delayed at least 15 minutes.

Who is Replimune Group's CEO?

Dr. Sushil Patel Ph.D. is the chief executive officer of Replimune Group Inc., which has about 465 employees.

What is the REPL 52-week high?

The 52-week high for REPL is $23.54 and the 52-week low is $1.50. The stock is currently 19.0% below its high.

Compare REPL